PHILADELPHIA, PA — FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The research highlights significant findings and the progress of plixorafenib in treating patients with BRAF-mutated cancers.
One presentation will showcase data demonstrating that circulating tumor DNA (ctDNA) effectively detects BRAF mutations and could serve as a marker for monitoring disease progression. These results, derived from an exploratory endpoint in a Phase 1/2a study, underscore the potential of ctDNA in enhancing biomarker-driven approaches in cancer care.
The second presentation provides an in-depth look at the design of the ongoing Phase 2 FORTE basket study, which evaluates the efficacy of plixorafenib across multiple BRAF-mutated tumor types.
“Plixorafenib’s unique paradox breaking mechanism of action in tumors with BRAF alterations underscores its potential to redefine the standard of care for a patient population that has long been underserved,” said William Hinshaw, CEO of Fore. “We are excited to share these compelling data with the medical community at AACR. These findings continue to support plixorafenib as a potential best-in-class agent for BRAF-driven tumors.”
The posters will feature contributions from leading oncologists, including Dr. Rona Yaeger of Memorial Sloan Kettering Cancer Center and Dr. Karisa Schreck of Johns Hopkins University, and will provide valuable insights into plixorafenib’s clinical advancement.
FORE Biotherapeutics’ research represents a promising step toward innovative treatment options for patients affected by BRAF-mutated cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.